| 1 | Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis. (William BM, Wang T, Haagenson MD, Fleischhauer K, Verneris M, Hsu KC, de Lima MJ, Fernandez-Viña M, Spellman SR, Lee SJ, Hill BT) Biol Blood Marrow Transplant 2018 Apr;24(4):827-831 1 Citation |
| 2 | Allogeneic stem cell transplantation for multiple myeloma: is there a future? (Dhakal B, Vesole DH, Hari PN) Bone Marrow Transplant 2016 Apr;51(4):492-500 52 Citations |
| 1 | Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. (Satwani P, Jin Z, Martin PL, Bhatia M, Garvin JH, George D, Chaudhury S, Talano J, Morris E, Harrison L, Sosna J, Peterson M, Militano O, Foley S, Kurtzberg J, Cairo MS) Leukemia 2015 Feb;29(2):448-55 34 Citations |
| 1 | Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? (Klyuchnikov E, Bacher U, Kroll T, Shea TC, Lazarus HM, Bredeson C, Fenske TS) Bone Marrow Transplant 2014 Jan;49(1):1-7 31 Citations |
| 1 | Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. (Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM) J Clin Oncol 2013 Apr 20;31(12):1530-8 179 Citations |
| 4 | Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. (Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG, Blood Marrow Transplant Clinical Trials Network (BMT CTN)) Lancet Oncol 2011 Dec;12(13):1195-203 250 Citations |
| 2 | Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. (Ringdén O, Shrestha S, da Silva GT, Zhang MJ, Dispenzieri A, Remberger M, Kamble R, Freytes CO, Gale RP, Gibson J, Gupta V, Holmberg L, Lazarus H, McCarthy P, Meehan K, Schouten H, Milone GA, Lonial S, Hari PN) Bone Marrow Transplant 2012 Jun;47(6):831-7 27 Citations |
| 1 | CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells. (Liu K, Anthony BA, Yearsly MM, Hamadani M, Gaughan A, Wang JJ, Devine SM, Hadley GA) PLoS One 2011;6(7):e21968 10 Citations |
| 1 | Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. (Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG) Biol Blood Marrow Transplant 2011 Jul;17(7):1051-7 62 Citations |
| 3 | Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. (Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, Drobyski W, Wang D, Pavletic S, Ringden O, Horowitz MM, Collins R Jr) Bone Marrow Transplant 2008 Aug;42(3):201-5 41 Citations |
| 1 | Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. (Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, Devine SM) Biol Blood Marrow Transplant 2008 Apr;14(4):480-3 34 Citations |
| 2 | Allogeneic hematopoietic cell transplantation for metastatic breast cancer. (Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D) Bone Marrow Transplant 2008 Mar;41(6):537-45 44 Citations |
| 2 | Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. (Bierman PJ, Sweetenham JW, Loberiza FR Jr, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, Horowitz M, Goldstone A, Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation) J Clin Oncol 2003 Oct 15;21(20):3744-53 136 Citations |
| 1 | Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. (Porter DL, Collins RH Jr, Shpilberg O, Drobyski WR, Connors JM, Sproles A, Antin JH) Biol Blood Marrow Transplant 1999;5(4):253-61 99 Citations |
| 3 | T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. (Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 1999 Jul 15;94(2):434-41 78 Citations |
| 1 | Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. (Johnson BD, Becker EE, Truitt RL) Biol Blood Marrow Transplant 1999;5(3):123-32 54 Citations |
